Nanjing Qingpu

A Global Leader in Pain Management Drug Innovation

Nanjing, China · Founded 2017 · $100.7M raised

Headquarters
Nanjing
Employees
51–200
Founded
2017
Business Model
B2B
Total Funding
$100.7M
Last Round
Venture RoundJul 2026
Rounds
3

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Nanjing Delova Biotech (Nanjing Qingpu Biotechnology) is a 2017 Nanjing-based biopharmaceutical company that develops non-addictive, non-opioid drugs for unmet pain-management needs. It has built proprietary long-acting injectable platforms that can sustain drug release for days, weeks, or months, and a team spanning discovery through commercialization. In April 2025 its Putanning / QAMZOVA meloxicam injection was approved in both China and the United States, the first Chinese analgesic new drug to receive FDA marketing authorization. Delova also has more than ten novel non-opioid pipeline candidates, including QP002, QP-6211, and QP-5113.

Summary

Nanjing Qingpu is a Biotech company based in Nanjing, China, founded in 2017. It has raised $100.7M in total across 3 rounds, most recently a Venture Round in Jul 2026. Investors include Partners Investment.

Funding History

Series CSeries CJul 2026
$89.0M

Sign up to see all 3 events

Funding: Series A through Series C. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Nanjing Qingpu on Indexed.vc
<a href="https://indexed.vc/companies/nanjing-qingpu"><img src="https://indexed.vc/api/badge/company/nanjing-qingpu" alt="Nanjing Qingpu on Indexed.vc" width="260" height="76" /></a>